Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of cetuximab when given together
with everolimus in treating patients with metastatic or recurrent colon cancer or head and
neck cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of the tumor to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Everolimus may stop the growth of
tumor cells by blocking blood flow to the tumor. Giving cetuximab together with everolimus
may be an effective treatment for colon cancer or head and neck cancer